Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269589 | 0.93 | KCNH2 (0.63) | CACNA1IKCNH2MEN1KMT2ATAS1R3 | |
| SCHEMBL15353976 | 0.88 | CACNA1I (0.56) | CACNA1IKCNH2KMT2ACACNA1GCACNA1H | |
| SCHEMBL8373982 | 0.88 | CACNA1I (0.56) | CACNA1IKCNH2KMT2ACACNA1GCACNA1H | |
| SCHEMBL8371543 | 0.86 | CACNA1I (0.58) | CACNA1IKCNH2CACNA1GCACNA1HCCR2 | |
| SCHEMBL15353986 | 0.86 | CACNA1I (0.56) | CACNA1IKCNH2MEN1KMT2ACACNA1G | |
| SCHEMBL20056227 | 0.84 | KCNH2 (0.56) | CACNA1IKCNH2MEN1KMT2ATAS1R3 | |
| SCHEMBL15353983 | 0.83 | CACNA1I (0.55) | CACNA1IKCNH2CACNA1GCACNA1HCCR2 | |
| SCHEMBL8374246 | 0.83 | CACNA1I (0.60) | CACNA1IKCNH2CACNA1GCACNA1HCCR2 | |
| SCHEMBL8371769 | 0.83 | CACNA1I (0.59) | CACNA1IKCNH2CACNA1GCACNA1HCCR2 | |
| SCHEMBL8376031 | 0.83 | CACNA1I (0.62) | CACNA1IKCNH2CACNA1GCACNA1HCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885MEN1 3293/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1I 4/4885KCNH2 60/4885MEN1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.